STERIS plc

STE

$224.36

-0.79%

2026-09-04 10:27:10 EDT-$1.78

Healthcare

Medical - Specialties

NYSE

Active Trading

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, ...

Price Action of STE

$224.36

-0.79%-$1.78

High—

Low—

52W High-16.3%

Rel. vol—

Interval

Range6.4h

Volume—SMA5SMA10

—

STERIS plc, headquartered in Dublin, Ireland, operates globally with a workforce of over 18,000 employees across more than 100 countries. The company is structured into three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a wide range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing ...STERIS plc, headquartered in Dublin, Ireland, operates globally with a workforce of over 18,000 employees across more than 100 countries. The company is structured into three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a wide range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. Additionally, STERIS provides essential services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers. The company is a key player in the medical specialties industry, with a market capitalization of approximately $23.1 billion. Financially, STERIS demonstrates robust margins: gross profit margin at 44.4%, operating profit margin at 18.9%, and net profit margin at 13.3%. It has a strong balance sheet with a current ratio of 5.886 and a quick ratio of 2.96, reflecting solid liquidity. With a price-to-earnings ratio of 28.96, the company is valued for its growth potential, and it pays a dividend yield of 1.1%. STERIS has a rich history, founded in 1985 as Innovative Medical Technologies and renamed in 1987, with roots tracing back to the American Sterilizer Company founded in 1894. Leadership under President and CEO Daniel A. Carestio since July 2021 has continued to drive innovation in infection prevention, ensuring patient safety and operational efficiency for healthcare providers worldwide.ExpandCollapse

Founded

1985

Employees

17937

CEO

Daniel A. Carestio

Full Name

STERIS plc

Sector

Healthcare

Industry

Medical - Specialties

ROE

11.27%

Market Cap

$21.88B

Current Ratio

1.91

WACC

8.37%

ROIC

9.30%

Contact Information

https://www.steris.com

353 1 232 2000

5960 Heisley Road, Mentor, OH 44060

Key Metrics of STE

Snapshot

Latest / TTM · 6 periods

Market Cap

$21.88B

ROCE

12.1%

EV / EBITDA

13.07x

+0.6% YoY

FCF Yield

4.2%

-0.3% YoY

Cash Conversion Cycle

101.3d

Current Ratio

1.91

Quick take

TTM —

Positive CCC

Financial Highlights of STE

Profitability trend

Latest / TTM · 6 periods

Gross Margin

44.4%

Net Margin

13.3%

P/E Ratio

27.66x

n/a

Debt / Equity

0.28

n/a

Current Ratio

1.91

Dividend Yield

1.1%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of STE

Upcoming

Sep 4, 2026Today
Ex-dividend date
$2.52 per share
Sep 25, 2026In 21 days
Dividend payment
$2.52 per share
Dec 30, 2026
Q3 FY2027 · Estimated results
Est. EPS $2.81 · Revenue $1.61B · 4 analysts
Mar 30, 2027
Q4 FY2027 · Estimated results
Est. EPS $3.15 · Revenue $1.71B · 1 analysts

Recent history

Aug 7, 2026
Q1 FY2027 · Results reported
EPS $2.04 · Revenue $1.49B
View filing
May 29, 2026
FY2026 · Annual results
EPS $7.93 · Revenue $5.94B
View filing
Feb 6, 2026
Q3 FY2026 · Results reported
EPS $1.96 · Revenue $1.50B
View filing
Nov 6, 2025
Q2 FY2026 · Results reported
EPS $1.94 · Revenue $1.46B
View filing
Aug 7, 2025
Q1 FY2026 · Results reported
EPS $1.79 · Revenue $1.39B
View filing
May 29, 2025
FY2025 · Annual results
EPS $6.20 · Revenue $5.46B
View filing

Financial Statements of STE

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$5.9B	+8.7%	-6.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$785.1M	+27.7%	-9.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+44.2%	+0.5%	+4.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+18.6%	+16.9%	-4.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+13.2%	+17.5%	-3.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$972.4M	+25.0%	+14.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+16.4%	+15.0%	+21.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	29.1%	-12.9%	-2.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.09x	+6.8%	-8.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$10.7B	+5.8%	-0.0%

Actual vs Estimate

A Mar 31Q Dec 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	7.93 vs 10.20	-22.2%	2.04 vs 2.81	-27.4%
Revenue Surprise	$5.9B vs $5.9B	-0.1%	$1.5B vs $1.6B	-7.4%

Insider Transactions of STE

Acquisitions (A)

Since Aug 10, 2026

Disposals (D)

Since Aug 10, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 12, 2026	Sohi Mohsen	director	Ordinary Shares	A	4,058	$86.23
Aug 12, 2026	Sohi Mohsen	director	Ordinary Shares	D	4,058	$235.78
Aug 12, 2026	Sohi Mohsen	director	Director Stock Option (right to buy)	D	4,058	$86.23
Aug 10, 2026	Sohi Mohsen	director	Career Restricted Stock Units	A	1,229	—
Aug 10, 2026	Sohi Mohsen	director	Director Stock Option (right to buy)	A	1,099	$238.91

Earnings Call Transcript of STE

1 transcript segments

Q4 2026

Unknown Speaker

Operator: Good day, and welcome to the STERIS plc Fourth Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Julie Winter, Investor Relations. Please go ahead. Julie Winter: Thank you, Chad, and good morning, everyone. Speaking on today's call will be Karen Burton, our Senior Vice President and CFO; and Dan Carestio, our President and CEO. And I do have a few words of caution before we open for comments. This webcast contains time-sensitive information that is accurate only as of today. Any redistribution, retransmission or rebroadcast of this call without the express written consent of STERIS is strictly prohibited. Some of the statements made during this review are or may be considered forward-looking statements. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in STERIS' securities filings. The company does not undertake to update or revise any forward-looking statements as a result of new information or future events or developments. STERIS' SEC filings are available through the company and on our website. In addition, on today's call, non-GAAP financial measures, including adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth and free cash flow, will be used. Additional information regarding these measures, including definitions, is available in our press release as well as reconciliations between GAAP and non-GAAP financial measures. Non-GAAP financial measures are presented during this call with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision-making. With those cautions, I will hand the call over to Karen. Karen Burton: Thank you, Julie, and good morning, everyone. It is my pleasure to be with you this morning to review the highlights of our fourth quarter performance from continuing operations. As anticipated, we ended the strong year with a lighter fourth quarter. For the fourth quarter, total as reported revenue grew 7%. Constant currency organic revenue grew 5% in the quarter, driven by volume as well as 230 basis points of price. Gross margin for the quarter was 44%, down 30 basis points versus the prior year. We continue to realize positive pricing, which helped mitigate the impact of higher tariffs and inflation. EBIT margin for the quarter was 24.2% of revenue, a high for fiscal 2026. This was 60 basis points below the fourth quarter last year mainly driven by inflation and tariffs. Incremental tariffs impacted our fourth quarter by approximately $10 million which was below our expectations due to lower volumes in materials and products sourced from outside the U.S. The adjusted effective tax rate in the quarter was …

Leadership Team of STE

12 executives

Name	Title	Compensation	Gender	Year Born	Status
Daniel A. Carestio	President, Chief Executive Officer & Director	USD 2,840,320	Male	1973	Active
Andrew Xilas	Senior Vice President & GM of Dental	USD 1,438,246	Male	1965	Active
Walter Rosebrough Jr.	Chief Executive Officer Emeritus & Senior Advisor	USD 1,156,398	Male	1954	Active
John Adam Zangerle	Senior Vice President, General Counsel & Secretary	USD 1,126,142	Male	1967	Active
Karen L. Burton	Senior Vice President, Chief Financial Officer & Chief Accounting Officer	USD 1,039,232	Female	1968	Active
Cary L. Majors	Senior Vice President & President of Healthcare	USD 1,028,172	Male	1975	Active
Mary Clare Fraser	SVP & Chief Human Resources Officer	USD 854,779	Female	1970	Active
Renato G. Tamaro	Vice President & Corporate Treasurer	—	Male	1969	Active
Julie Winter	Vice President of Investor Relations & Corporate Communications	—	Female	—	Active
Lindsey McGowan	VP, Chief Compliance & Quality Officer	—	Female	—	Active
Kenneth E. Kohler	Senior Vice President & GM of AST	—	Male	1963	Active
Julia K. Madsen	Senior Vice President & GM of Life Sciences	—	Female	1965	Active

Recent News of STE

Seeking Alpha8/6/2026Neutral

STERIS plc (STE) Q1 2027 Earnings Call Transcript

Zacks Investment Research8/6/2026Neutral

STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading

STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.

Zacks Investment Research8/6/2026Neutral

5 Quality Stocks Set to Reward Investors With Dividend Hikes

Recent dividend hikes from DRH, STE, BCC, KWR and WHD highlight financially solid companies as investors seek stability in a mixed market.

Zacks Investment Research8/5/2026Neutral

Here's What Key Metrics Tell Us About Steris (STE) Q1 Earnings

While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research8/5/2026Neutral

Steris (STE) Q1 Earnings Surpass Estimates

Steris (STE) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.54 per share. This compares to earnings of $2.34 per share a year ago.

Historical Employee Count of STE

Current

17,937

Change

-0.35%

Minimum

16,000

Maximum

18,179

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Mar 31, 2026	17,937	10-K	May 29, 2026	View
Mar 31, 2025	18,000	10-K	May 29, 2025	View
Mar 31, 2024	18,179	10-K	May 29, 2024	View
Mar 31, 2023	17,000	10-K	May 26, 2023	View
Mar 31, 2022	16,000	10-K	May 31, 2022	View

Related stocksMedical - Specialties

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

STERIS plc